TALE-Nuclease Design via Alternative RVD Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for designing TALE proteins are time-consuming and costly, with engineered TALE-nucleases often failing to achieve expected specificity and activity, and the assembly of tandem repeats for TALE binding domains is labor-intensive, particularly when constructing expression plasmids.
Innovation Solution
A method involving the systematic study of RVDs NN, NG, NI, and HD interactions with nucleic acid bases A, T, C, and G to establish a new matrix for TALE code, allowing for the design of repeat arrays with improved specificity and flexibility by introducing alternative RVDs, such as NI targeting T or G, and HD or NG targeting G, to optimize TALE-nuclease activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional TALE protein design methods are used, then TALE-nucleases can be constructed, but the design process is time-consuming and costly
Solution Approach 1:
The patent pre-establishes a comprehensive matrix mapping RVDs to nucleic acid bases through systematic study of interactions between RVDs (NN, NG, NI, HD) and bases (A, T, C, G). This preliminary work creates a ready-to-use reference that eliminates the need for time-consuming experimental determination of RVD-specificity relationships during each new TALE design project.
Solution Approach 2:
The patent creates a standardized code matrix that can be copied and applied repeatedly to design different TALE-nucleases. Once the RVD-base relationships are established in the matrix, this knowledge can be directly copied to design multiple different TALE proteins without repeating the systematic study, significantly reducing design time for subsequent applications.
2Ease of manufacture
If traditional TALE assembly methods are used, then TALE binding domains can be constructed, but the assembly of tandem repeats is labor-intensive
Solution Approach 1:
The patent divides the TALE binding domain into modular repeat units, each containing specific RVDs that can be independently selected based on the desired target sequence. This segmentation allows researchers to assemble TALE proteins by simply concatenating standardized modular units rather than performing complex de novo assembly, greatly simplifying the construction process.
Solution Approach 2:
The patent changes the design parameter from custom-designed unique repeats to standardized modular repeats with defined RVD compositions. By establishing fixed relationships between RVDs and nucleic acid bases in the matrix, the patent transforms the design process into a parameter selection task rather than a complex assembly task, reducing labor intensity.
3Reliability
If engineered TALE-nucleases are constructed using existing methods, then they can target DNA sequences, but they often fail to achieve expected specificity and activity
Solution Approach 1:
The patent incorporates experimental validation data into the matrix creation process, where the actual binding specificities of different RVDs are determined and fed back into the design guidelines. This feedback loop ensures that the matrix reflects real-world performance rather than theoretical predictions, improving the reliability of subsequent TALE designs.
Solution Approach 2:
The patent refines the specificity parameters by establishing precise RVD-base mapping rules based on systematic experimental data. By determining the actual binding preferences of each RVD (e.g., which bases NI, HD, NG, NN preferentially bind), the patent creates more accurate design parameters that lead to TALE-nucleases achieving their expected specificity.
4Measurement precision
If comprehensive RVD studies are conducted to establish accurate targeting rules, then design accuracy improves, but the study process becomes more complex and resource-intensive
Solution Approach 1:
The patent creates a universal matrix that serves multiple functions: it predicts TALE binding specificity, guides TALE-nuclease design, and provides a reference for interpreting experimental results. By establishing this comprehensive but standardized framework once, the patent enables accurate specificity prediction for numerous different TALE designs without repeating complex studies, reducing overall research complexity.
Data Source
AI summary
Methods for improving or modulating targeting specificity of TALE proteins by introducing alternative RVDs into their modular nucleic acid binding domains. Polynucleotides encoding TALE proteins having alternative targeting specificity towards a nucleic acid target sequence. TALE proteins having alternative targeting specificity towards a nucleic acid target sequence and methods of making and using them.